Kodak's $765M manufacturing loan on the rocks as red flags multiply
Kodak, once famous for its cameras, has been rocked by insider trading allegations in recent days. (Pixabay)
Eastman Kodak's unlikely deal with the federal government to dive into drug manufacturing has raised eyebrows—not only for the size of the loan itself but Kodak's lack of experience. Now, with investigations mounting, the U.S. is pumping the brakes.
The government put the $765 million loan on hold after "allegations of wrongdoing" on the company's part jeopardized its federally funded move into pharmaceuticals, the U.S. International Development Finance Corporation (DFC) said in a terse tweet Friday.
Kodak and the DFC signed an interest letter in late July for a loan that would have jumpstarted Kodak's move into manufacturing active pharmaceutical ingredients (API) for a range of generic drugs.
ESMO Post Show: Highlights from the Virtual Conference
Cancer experts and pharma execs will break down the headline-making data from ESMO, sharing their insights and analysis around the conference’s most closely watched studies. This discussion will examine how groundbreaking research unveiled over the weekend will change clinical practice and prime drugs for key new indications, and panelists will fill you in on the need-to-know takeaways from oncology’s hottest fields. Register today.
The government's interest in Kodak—a photography company that declared bankruptcy in 2012 and has limited experience in drugmaking—as well as insider trading allegations spurred a growing number of investigations in recent days.
On July 28, we signed a Letter of Interest with Eastman Kodak. Recent allegations of wrongdoing raise serious concerns. We will not proceed any further unless these allegations are cleared.